Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals, Inc. (AVIR) is a clinical-stage biopharmaceutical company pioneering oral antiviral therapies for severe viral diseases. This page provides investors and healthcare professionals with timely updates on clinical trial progress, regulatory milestones, and corporate developments.
Key resources include: Press releases detailing study results, partnership announcements with research institutions, and financial disclosures. Track updates on COVID-19 therapeutic candidates, hepatitis C treatments, and emerging programs targeting RNA viruses.
All content is sourced directly from company filings and official communications to ensure accuracy. Visitors can expect detailed coverage of Phase 2/3 trial outcomes, FDA interactions, and strategic initiatives advancing antiviral drug development.
Bookmark this page for consolidated access to AVIR's latest scientific advancements and business updates. Check regularly for new developments from Atea's nucleos(t)ide prodrug platform and pipeline expansion efforts.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi will present a business update at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 3:00 p.m. PT in San Francisco. A live webcast of the presentation will be available on Atea's website and will remain accessible for 90 days. Atea, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for severe viral diseases, including COVID-19, dengue, and hepatitis C.
Atea Pharmaceuticals (AVIR) has initiated the SUNRISE-3 Phase 3 trial to evaluate bemnifosbuvir, an oral antiviral treatment for COVID-19, in high-risk non-hospitalized patients. The trial aims to enroll at least 1,500 participants and will assess its efficacy against hospitalization and death. Bemnifosbuvir targets the SARS-CoV-2 RNA polymerase, boasting a unique mechanism that helps mitigate resistance. Previous late-stage trials indicated a 71% reduction in hospitalization rates for treated patients compared to placebo. This development highlights Atea's focus on unmet medical needs in COVID-19 treatment.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi and the management team will present a business update at the 5th Annual Evercore ISI HealthCONx Conference on November 29 at 9:40 a.m. ET. A live webcast will be available on the company’s website, with an archived version accessible for 90 days post-event.
Atea focuses on developing oral antiviral therapies for severe diseases, including COVID-19, hepatitis C, and dengue, leveraging its nucleos(t)ide prodrug platform to address unmet medical needs.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi will present a business update at the Jefferies London Healthcare Conference on November 15, 2022, at 5:00 p.m. GMT / 12:00 p.m. ET. The event will be accessible via a live webcast and archived for 90 days post-event. Atea focuses on developing oral therapies for severe viral infections, leveraging its nucleos(t)ide prodrug platform. Current efforts include targeting COVID-19, hepatitis C, and other severe viral diseases.
Atea Pharmaceuticals (Nasdaq: AVIR) announced key updates and financial results for Q3 2022, reporting a net loss of $8.1 million, down from a loss of $28.2 million in 2021. The company holds $665 million in cash and marketable securities. Notably, the SUNRISE-3 trial for bemnifosbuvir in high-risk COVID-19 patients is set to enroll before year-end 2022. Additionally, Atea plans to submit trial applications for a hepatitis C combination study. Research and development expenses decreased significantly, attributed to the termination of a cost-sharing agreement with Roche.
Atea Pharmaceuticals (AVIR) provided updates on AT-752, an oral antiviral for dengue fever, during the ASTMH 2022 Annual Meeting. The Phase 1 trial showed that AT-752 was well tolerated at doses up to 1500 mg, achieving plasma levels above the in vitro EC90. The FDA has given Fast Track designation for AT-752, making it a promising option for treating dengue, which affects 400 million annually. Atea is advancing two proof-of-concept studies to evaluate AT-752's safety and efficacy against dengue, aiming to fill the existing treatment gap.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) will host a live conference call on November 7, 2022, at 4:30 p.m. ET, to report financial results for Q3 2022 and provide a business update. The call can be accessed via registration, with a webcast available in the Investor Relations section of the company's website. Atea focuses on developing oral therapies for severe diseases, particularly targeting ssRNA viruses, including SARS-CoV-2, HCV, dengue, and RSV. The company aims to expand its antiviral pipeline through its proprietary nucleos(t)ide prodrug platform.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that the FDA granted Fast Track Designation to AT-752, an oral antiviral for dengue treatment. This designation aims to expedite development, acknowledging the urgent need for effective treatments as there are currently no approved options. AT-752 has shown promising preclinical activity against dengue and safety in Phase 1 trials. The company is advancing two Phase 2 studies to assess AT-752’s efficacy and safety in adults with dengue virus infections, with initial data expected soon.
Atea Pharmaceuticals (Nasdaq: AVIR) announced a global Phase 3 trial to assess bemnifosbuvir for COVID-19, beginning in Q4 2022. The trial targets high-risk non-hospitalized patients, evaluating bemnifosbuvir as both monotherapy and in combination with other treatments. Previous trials indicated a 71% reduction in hospitalization rates. The randomized, double-blind study aims to enroll 1,500 patients across 300 sites worldwide, focusing on safety and efficacy against various COVID-19 variants. Positive early results emphasize bemnifosbuvir's potential as a cornerstone therapy for COVID-19 treatment.
Atea Pharmaceuticals (Nasdaq: AVIR) announced participation in key investor events on September 13, 2022. The management will host a conference call at 8:30 a.m. ET to detail the global Phase 3 trial of bemnifosbuvir for COVID-19 treatment. Additionally, CEO Jean-Pierre Sommadossi will engage in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference at 12:55 p.m. ET. Live webcasts of these events will be available on Atea's website.